This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00662-08v1 52/10/3637    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Lass-Flörl, C. Articles by Fille, M. PubMed PubMed Citation Articles by Lass-Flörl, C. Articles by Fille, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3637-3641, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00662-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

Department of Hygiene, Microbiology and Social Medicine, Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria

Received 20 May 2008/ Returned for modification 25 June 2008/ Accepted 28 July 2008

We compared the activities of antifungal agents against a wide range of yeasts and filamentous fungi. The methodology of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for yeasts and spore-forming molds was applied; and a total of 349 clinical isolates of Candida spp., other yeast species, Aspergillus spp., and nondermatophyte non-Aspergillus spp. were investigated. The average geometric mean (GM) of the MICs of the various drugs for Candida spp. were as follows: amphotericin B (AMB), 0.55 µg/ml; liposomal amphotericin B (l-AMB); 0.35 µg/ml; itraconazole (ITC), 0.56 µg/ml; voriconazole (VRC), 0.45 µg/ml; posaconazole (POS), 0.44 µg/ml; and caspofungin (CPF), 0.45 µg/ml. The data indicated that the majority of Candida spp. were susceptible to the traditional and new antifungal drugs. For Aspergillus spp., the average GM MICs of AMB, l-AMB, ITC, VRC, POS, and CPF were 1.49 µg/ml, 1.44 µg/ml, 0.65 µg/ml, 0.34 µg/ml, 0.25 µg/ml, and 0.32 µg/ml, respectively. For the various zygomycetes, the average GM MICs of AMB, l-AMB, ITC, and POS were 1.36 µg/ml, 1.42 µg/ml, 4.37 µg/ml, and 1.65 µg/ml, respectively. Other yeastlike fungi and molds displayed various patterns of susceptibility. In general, the minimal fungicidal concentrations were 1 to 3 dilutions higher than the corresponding MICs. POS, AMB, and l-AMB showed activities against a broader range of fungi than ITC, VRC, and CPF did. Emerging pathogens such as Saccharomyces cerevisiae and Fusarium solani were not killed by any drug. In summary, the EUCAST data showed that the in vitro susceptibilities of yeasts and filamentous fungi are variable, that susceptibility occurs among and within various genera and species, and that susceptibility depends on the antifungal drug tested. AMB, l-AMB, and POS were active against the majority of pathogens, including species that cause rare and difficult-to-treat infections.

Published ahead of print on 11 August 2008.